Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet
Craig H MoskowitzAETHERA Study Group

Abstract

High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of patients might be cured after autologous stem-cell transplantation; however, most patients with unfavourable risk factors progress after transplantation. We aimed to assess whether brentuximab vedotin improves progression-free survival when given as early consolidation after autologous stem-cell transplantation. We did this randomised, double-blind, placebo-controlled, phase 3 trial at 78 sites in North America and Europe. Patients with unfavourable-risk relapsed or primary refractory classic Hodgkin's lymphoma who had undergone autologous stem-cell transplantation were randomly assigned, by fixed-block randomisation with a computer-generated random number sequence, to receive 16 cycles of 1·8 mg/kg brentuximab vedotin or placebo intravenously every 3 weeks, starting 30-45 days after transplantation. Randomisation was stratified by best clinical response after completion of salvage chemotherapy (complete response vs partial response vs stable disease) and primary refractory Hodgkin's lymphoma versus relapsed disease less than 12 months after completion of fron...Continue Reading

Citations

Mar 1, 2019·Bioscience Reports·Nahla Hamed AnberSameh S Shamaa
Mar 16, 2019·Expert Review of Hematology·Parastoo B DahiHillard M Lazarus
Mar 26, 2019·Expert Review of Clinical Pharmacology·Davide BusatoMichele Dal Bo
May 18, 2019·American Society of Clinical Oncology Educational Book·Alison J MoskowitzAnne W Beaven
Mar 13, 2019·Journal of the National Cancer Institute·Michael J BirrerRichard C Bates
Apr 11, 2018·American Journal of Hematology·Stephen M Ansell
Jan 21, 2017·Clinical Journal of Oncology Nursing·Amy GoodrichDana Delibovi
Aug 10, 2017·Expert Opinion on Emerging Drugs·Anna Wolska-WasherTadeusz Robak
Oct 4, 2019·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Clement Chung
Aug 20, 2019·Journal of the National Cancer Institute. Monographs·M CarrozzoD E Peterson
Jan 15, 2020·Blood Advances·Armando SantoroCarmelo Carlo-Stella
Aug 26, 2017·Current Opinion in Oncology·Katerina Benekou, Silvia Montoto
May 14, 2020·Journal of Clinical Medicine·Eva Domingo-Domènech, Anna Sureda
Sep 11, 2019·Journal of Hematology & Oncology·Bo Yu, Delong Liu
Jun 9, 2020·British Journal of Haematology·Lourdes CalventeRobert Kridel
May 10, 2020·American Journal of Hematology·Stephen M Ansell
Jun 20, 2020·British Journal of Haematology·Peter HoklandJudith Trotman
Jun 6, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Richard T HoppeNdiya Ogba
Jul 18, 2020·Future Oncology·Liana Nikolaenko, Auayporn Nademanee
Aug 7, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Aliza Gardenswartz, Mitchell S Cairo
Apr 1, 2017·Expert Review of Hematology·Eva M DonatoJavier De La Rubia
Mar 28, 2017·Bone Marrow Transplantation·F CovutP F Caimi
May 6, 2017·Therapeutic Advances in Hematology·Nathan D GayEmma C Scott
Jul 18, 2015·British Journal of Haematology·Karl S Peggs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.